X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Abbott India with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs TEVA PHARMA (Israel) - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   TEVA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
TEVA PHARMA
Dec-13
ABBOTT INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1103,001-   
Low Rs3,9962,607-   
Sales per share (Unadj.) Rs1,552.21,722.1-  
Earnings per share (Unadj.) Rs188.8107.6-  
Cash flow per share (Unadj.) Rs196.4246.8-  
Dividends per share (Unadj.) Rs55.0094.18-  
Dividend yield (eoy) %1.13.4 32.4%  
Book value per share (Unadj.) Rs796.61,913.0-  
Shares outstanding (eoy) m21.25848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.6 200.0%   
Avg P/E ratio x26.826.1 102.7%  
P/CF ratio (eoy) x25.711.4 226.4%  
Price / Book Value ratio x6.31.5 432.8%  
Dividend payout %29.187.5 33.3%   
Avg Mkt Cap Rs m107,3762,377,546 4.5%   
No. of employees `0003.344.9 7.4%   
Total wages/salary Rs m3,9370-   
Avg. sales/employee Rs Th9,929.332,492.5 30.6%   
Avg. wages/employee Rs Th1,185.10-   
Avg. net profit/employee Rs Th1,207.72,029.8 59.5%   
INCOME DATA
Net Sales Rs m32,9851,460,373 2.3%  
Other income Rs m1,1700-   
Total revenues Rs m34,1551,460,373 2.3%   
Gross profit Rs m5,245399,924 1.3%  
Depreciation Rs m162118,043 0.1%   
Interest Rs m3828,684 0.1%   
Profit before tax Rs m6,215253,197 2.5%   
Minority Interest Rs m01,150 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-166,210 0.0%   
Tax Rs m2,203-3,091 -71.3%   
Profit after tax Rs m4,01291,228 4.4%  
Gross profit margin %15.927.4 58.1%  
Effective tax rate %35.4-1.2 -2,903.0%   
Net profit margin %12.26.2 194.7%  
BALANCE SHEET DATA
Current assets Rs m22,655986,331 2.3%   
Current liabilities Rs m6,681860,164 0.8%   
Net working cap to sales %48.48.6 560.5%  
Current ratio x3.41.1 295.7%  
Inventory Days Days6591 71.3%  
Debtors Days Days2996 30.4%  
Net fixed assets Rs m835476,990 0.2%   
Share capital Rs m2133,595 5.9%   
"Free" reserves Rs m16,7150-   
Net worth Rs m16,9281,622,198 1.0%   
Long term debt Rs m0746,721 0.0%   
Total assets Rs m24,1623,337,421 0.7%  
Interest coverage x163.79.8 1,665.7%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.40.4 312.0%   
Return on assets %16.83.6 466.6%  
Return on equity %23.75.6 421.5%  
Return on capital %36.94.9 749.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,4380-   
CASH FLOW
From Operations Rs m1,527232,708 0.7%  
From Investments Rs m-2,148-82,458 2.6%  
From Financial Activity Rs m-1,024-279,149 0.4%  
Net Cashflow Rs m-1,646-128,899 1.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare ABBOTT INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare ABBOTT INDIA With: TORRENT PHARMA  PANACEA BIOTECH  J.B.CHEMICALS  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 16, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS